Lunit Makes Full-Fledged Entry into the Middle East with Participation in ‘Saudi Vision 2030’ Healthcare Transformation Project

Lunit's AI-powered cancer screening solutions have been selected for Seha Virtual Hospital's AI evaluation and clinical integration project.Successful validation to be followed by supply contract to assist Saudi Arabia's national cancer and tuberculosis screening program.

Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the collaboration with Seha Virtual Hospital (SVH) in Riyadh, Kingdom of Saudi Arabia. The partnership seeks to contribute to driving healthcare transformation across Saudi Arabia, aligning with the Kingdom’s ‘Saudi Vision 2030’ strategy.

Under the project, Lunit has successfully delivered Lunit INSIGHT CXR, its AI solution for chest x-ray image analysis, and Lunit INSIGHT MMG, an AI solution for mammography analysis, to Seha Virtual Hospital for validation and integration purposes.

After the ongoing evaluation to confirm potential clinical benefits, both solutions are expected to be rolled out to more than 170 medical sites throughout Saudi Arabia as part of the national cancer and tuberculosis screening program.

Established in 2022, Seha Virtual Hospital is a cornerstone of the Kingdom’s healthcare innovation, which is the key initiative of the ‘Saudi Vision 2030’. As the world’s largest virtual hospital and the first of its kind in the Middle East, SVH plays a pivotal role in supporting 170 hospitals and providing medical services to 480,000 patients annually.

By integrating Lunit INSIGHT suite into their virtual cancer screening workflow, Seha Virtual Hospital aims to offer advanced examinations for patients and enhance the effectiveness of the national cancer screening program.

During the recent Hajj season, which took place from June 26 to July 1 and attracted 2 million pilgrims from 160 countries, Seha Virtual Hospital utilized Lunit INSIGHT CXR to detect chest abnormalities and prevent their spread.

“We are delighted to partner with Seha Virtual Hospital and contribute to the transformation of cancer diagnosis in Saudi Arabia,” said Brandon Suh, CEO of Lunit. “Given that Saudi Arabia boasts the largest medical market in the Gulf Cooperation Council, our highly promising partnership allows us to tap into this growing market. Through this collaboration, we aim to bring our innovative AI-powered solutions to healthcare providers throughout the Middle East, ultimately improving patient outcomes and making a significant impact on the fight against cancer.”

Lunit is actively extending its reach in the national cancer screening business through its collaboration with Seha Virtual Hospital, building upon the successful partnerships with Australia’s BreastScreen New South Wales (BSNSW) program last year and Capio St. Göran Hospital in Sweden earlier this year.

SourceLunit
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

LumiGuide, powered by Fiber Optic RealShape (FORS) technology, enables doctors to navigate through blood vessels using light, instead of X- ray. “[It’s] one of the most exciting changes that we’ve seen with imaging certainly throughout my career,” said Andres Schanzer, Vascular Surgeon, at UMass Memorial Medical Center, Worcester, MA, USA.
Carestream Health notes twenty-seven of the patents were awarded by the U.S. Patent and Trademark Office; an additional 43 patents were received in European and Asian countries.
According to an Insightec study, patients experienced significant reductions in upper limb tremor, tremor-related disability, and quality of life. The most common intraprocedural adverse events included dizziness, headache, nausea, and vomiting, which all resolved. Post-procedural adverse events included paraesthesia and gait disturbance, which were often transient or resolved within 12 months.
Chris Landon, Business Leader Image Guided Therapy Devices at Philips: “IVUS is a technology that has demonstrated an ability to both support safer procedures for patients and procedural staff alike including reductions in radiation exposure. As the global leader in IVUS solutions, we are grateful for the rigorous multidisciplinary approach to developing expert consensus on the value of IVUS and we look forward to working with all stakeholders to standardize the use of IVUS and reduce the barriers preventing utilization.”
"We are delighted to see our 3D solution CE-marked and available on the European market," says Ulrik Harrysson, CEO at SyntheticMR AB. "SyMRI 3D represents the next generation of quantitative MRI, offering unprecedented resolution and accuracy in brain imaging, revolutionizing the landscape of medical diagnostics."

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version